CTTH - CTT Pharma Update On European Patent
(TheNewswire)
Tampa, Florida, United States - TheNewswire - April 13, 2022 - CTTPharmaceutical Holdings, Inc. (OTC:CTTH) has made progress on numerouspatents that are pending. The latest correspondence from the EuropeanPatent Office(EPO) did not include any objections, indicating that thepatent office intends to grant CTT Pharma's European Patent in thenear future, as stated by our Patent Counsel. Once granted this patentcan be validated in 38 countries. Ryan Khouri, CEO of CTT Pharma,stated, "The indication for our European Patent is promising,as this patent would help CTT's global footprint by allowing ourpotential clients the ability to reach customers in 38countries." CTT Pharma will continue to update our shareholderson this patent as more news becomes available.
CTT is a drug delivery technology company that successfully receivedHealth Canada approval and helped to bring our first product to marketas cannabinoid-infused “Dissolve Strips”. This successful launchsold out to only 85,000 medical patients online with no advertising inseveral weeks. Once dissolved, CTT Pharma's strips enter thebloodstream bypassing the lungs and digestive tract including theliver. Our smoke-free dissolvable strips have better bioavailability,better absorption, faster onset, and can offer zero calories.Nicotine, CBD, THC, and many other actives can be used with ourpatented technology.
CTT common shares trade on the OTC market in the United States underthe symbol "CTTH"
Contact Ryan Khouri at 813-606-0060
www.linkedin.com/in/ryan-khouri-679a251b7
www.cttpharmaceuticals.com
Copyright (c) 2022 TheNewswire - All rights reserved.